Cobrabio and ViroMed Join Together for R&D Biomanufacturing
Cobra Biomanufacturing Plc (Keele, UK), a manufacturer of biopharmaceuticals, has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd. (Seoul, Korea), a specialist in the development of DNA and protein-based therapeutics.
Cobra Biomanufacturing Plc (Keele, UK), a manufacturer of biopharmaceuticals, has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd. (Seoul, Korea), a specialist in the development of DNA and protein-based therapeutics.
The extended collaboration includes a long-term research, development, and technical consultancy agreement for all ViroMed products. The agreement will provide ViroMed with guaranteed process development and manufacturing resources.
Additionally, the companies have signed a memorandum of understanding to explore the potential of establishing a joint venture (JV) commercial-scale biomanufacturing company that would enable the JV company to manufacture ViroMed products for commercial supply, at the JV’s new facilities.
These agreements extend the manufacturing collaboration announced in June 2008, under which Cobrabio will manufacture ViroMed’s plasmid DNA therapeutic, VM206RY, for the treatment of tumors expressing Her2/neu.
Cobrabio release
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
